Villers-lès-Nancy, 6 February 2025 - 6:00 p.m. (CET)
PRESS RELEASE
2024 annual revenue: €216.8 million including €58.6 million in Q4 (+2.6% on a reported basis and -0.4% like-for-like)
| Revenue (€&) | 2023 Reported basis | 2024
Reported basis | Change / Reported basis | Of which external growth | Of which Ségur1 2024 |
Of which Ségur 2023 | Like-for-like change
(organic growth) | |||
| Q1 | 56.2 | 53.3 | -2.9 | -5.2% | 2.0 | 0.3 | -1.4 | -3.8 | -6.7% | |
| Q2 | 56.4 | 54.7 | -1.7 | -3.0% | 1.7 | 0.3 | -1.2 | -2.6 | -4.6% | |
| Q3 | 50.1 | 50.2 | 0.1 | 0.3% | 1.8 | 0.2 | -0.3 | -1.5 | -3.0% | |
| Q4 | 57.0 | 58.6 | 1.5 | 2.6% | 1.7 | 0.2 | -0.3 | -0.2 | -0.4% | |
| Total | 219.7 | 216.8(*) | -3.0 | -1.4% | 7.2 | 1.1 | -3.2 | -8.2 | -3.7% | |
Note: Acquisitions in 2023 and 2024 (Atoopharm, Speach2Sense, Pratilog, ADV in Germany - now Pharmagest Germany) and Digipharmacie) have been restated in the scope of consolidation.
Maintaining a strategy of external growth, in December 2024 Equasens Group acquired 90% of the capital of Calimed SAS, a software publisher for private practitioners and surgeons (with no consolidated revenue in Q4 2024).
Equasens Group, (Euronext Paris™ - Compartment B - FR 0012882389 -EQS), a leading provider of digital solutions for healthcare professionals, reported full-year revenue for the 12-month period ending 31 December 2024 of €216.8m, contracting 1.4% on a reported basis. Like-for-like (organic growth), i.e. excluding the effects of acquisitions and the impact of the Ségur digital healthcare investment programme, revenue decreased by 3.7%.
| Annual revenue at 12/31/24 / Division (€m) | 2023 Reported basis | 2024
Reported basis | Change / Reported basis | Of which external growth | Of which Ségur 2024 |
Of which Ségur 2023 | Like-for-like change
(organic growth) | ||
| Pharmagest | 162.7 | 163.5 | 0.8 | 0.5% | 7.1 | 0.5 | -1.5 | -5.3 | -3.3% |
| Axigate Link | 31.1 | 32.1 | 1.0 | 3.2% | 0.3 | -1.0 | 1.7 | 5.5% | |
| e-Connect | 15.0 | 11.2 | -3.8 | -25.3% | -3.8 | -25.3% | |||
| Medical Solutions | 8.9 | 7.9 | -1.0 | -10.9% | 0.1 | 0.3 | -0.7 | -0.7 | -8.1% |
| Fintech | 2.0 | 2.0 | 0.0 | -2.1% | 0.0 | -2.1% | |||
| Total | 219.7 | 216.8 | -3.0 | -1.4% | 7.2 | 1.1 | -3.2 | -8.2 | -3.7% |
| FY revenue for the 12 month period ending 31 December 2024 / Activities (€m) | 2023 Reported basis | 2024 Reported basis | Change / Reported basis | |
| Sale of configurations and hardware | 93.5 | 86.1 | -7.4 | -7.9% |
| Scalable maintenance and professional training services | 78.1 | 81.0 | 2.8 | 3.6% |
| Software solutions and subscriptions | 45.4 | 46.8 | 1.4 | 3.0% |
| Other services (including intermediation) | 2.7 | 2.9 | 0.2 | 7.9% |
| Total | 219.7 | 216.8 | -3.0 | -1.4% |
| Q4 2024 revenue / Division (€m) | 2023 Reported basis | 2024 Reported basis | Change / Reported basis | Of which external growth | Of which Ségur 2024 | Of which Ségur 2023 | Like-for-like change (organic growth) | ||
| Pharmagest | 42.2 | 43.4 | 1.2 | 2.9% | 1.7 | 0.1 | -0.2 | -0.5 | -1.1% |
| Axigate Link | 8.9 | 9.5 | 0.7 | 7.6% | 0.1 | -0.1 | 0.7 | 7.7% | |
| e-Connect | 3.3 | 2.9 | -0.3 | -10.1% | -0.3 | -10.1% | |||
| Medical Solutions | 2.2 | 2.2 | 0.0 | -0.9% | 0.1 | -0.1 | 0.0 | -2.1% | |
| Fintech | 0.6 | 0.5 | -0.1 | -11.6% | -0.1 | -11.6% | |||
| Total | 57.1 | 58.6 | 1.5 | 2.6% | 1.7 | 0.3 | -0.4 | -0.2 | -0.4% |
| Q4 2024 revenue highlights by type of business | 2023 Reported basis | 2024 Reported basis | Change / Reported basis | |
| Sale of configurations and hardware | 23.2 | 23.5 | 0.1 | 0.4% |
| Scalable maintenance and professional training services | 19.8 | 20.4 | 0.6 | 3.1% |
| Software solutions and subscriptions | 13.2 | 13.8 | 0.5 | 4.1% |
| Other services (including intermediation) | 0.8 | 1.0 | 0.2 | 27.5% |
| Total | 57.1 | 58.6 | 1.5 | 2.6% |
- In a year marked by political instability, particularly in France, configuration and equipment sales were again heavily impacted on a full-year basis (-7.9%). The recovery initially anticipated in Q3 got off to a slower than expected start with marginal growth in Q4 (+0.4%).
- Scalable maintenance services and business training continued to display positive momentum with stable growth (+3.1 % in Q4 2024 and +3.6% for the full year).
- Software solutions and subscriptions performed particularly well in H2 after declining in the first half (reflecting the base effect from Ségur) to achieve 3% growth for the full year.
- The PHARMAGEST Division recorded annual sales of €163.5m (+0.5%) for the year ended 31 December 2024 on a reported basis, including €7.1m of restated sales arising from acquisitions in 2023 and 2024. On a like-for-like basis, sales for the division declined 3.3% for the full year.
- The Division's strategy of innovation and bringing new software, hardware and services to market has strengthened its value proposition in terms of pharmacy productivity and automation solutions starting in the third quarter, with, for example, the id.Express payment terminal deployed in France, Germany and Belgium, the new id.Genius module integrating AI into dispensing, and id.Assistance, a new service facilitating the use and adoption of the id. offering on a day-to-day basis.
- Based on these advances, the Pharmacy business now has a differentiating offering capable of generating revenue from its customer base (€2m at 31/12/2024) and contributing to growth in market share with more than 500 new customers in France and Italy (+€3.5m at 31/12/2024).
- Digipharmacie, a provider of digital accounts payable management solutions for pharmacies, recently approved as a partner of the French e-reporting platform (Plateforme de Dématérialisation Partenaire or PDP), recorded annual growth of 27%.
- The shift of the Division to SaaS offering culminated in the launch in September 2024 of the ASCA Dynamics solution, a cloud based version of the electronic label management software developed by Equasens Group. Nearly 250 of the 500 pharmacies added to ASCA's customer base in 2024 are already equipped with this solution.
- The AXIGATE LINK division registered €32.1m in revenue for the 12 month period ended 31 December 2024 (+3.2% on a reported basis and +5.5% like-for-like). In Q4 2024, the Division grew 7.6% to €9.5m on a reported basis compared with the same period in 2023. Like-for-like, the division's revenue grew 7.7% in the last quarter.
- The nursing home sector, which accounts for 53% of the Division's revenues, experienced a strong growth in 2024, with the addition of 104 new establishments (excluding the UK), bringing its installed base to a total of 3,400 sites. The Titanlink SaaS offering was a resounding success, more than 600 sites equipped out of a total of 2,500 in France and 90 in Belgium out of a total of 932.
- The Homecare sector also delivered a very solid performance, with a net gain of 20 customers, including 5 Hospital-at-Home programmes. In addition, the sector started rolling out the first version of a software package for regional elderly and disabled homecare centres (Centres de Ressources Territoriales or CRTs) to coordinate patient care. This activity accounts for 22% of the Division's revenue.
- The Hospital sector, 12% of the Division's revenue, grew 4.1% in 2024 compared with 2023 with a net increase of 7 facilities, including 3 major psychiatric establishments. A portion of these orders signed in 2024 will be implemented and recognised in revenue for 2025.
- The PandaLab Pro secure messaging system recently passed the milestone of 50,000 independent users or private organisations and 360,000 messages sent per month. 2024 experienced a growth in the number of use cases, particularly in teleconsultation, remote assistance and outpatient prescriptions, with the latter reaching 85,000 prescripti